advertisement
Wang Y 76
Showing records 1 to 25 | Display all abstracts from Wang Y104748 mTOR Signalling Pathway: A Potential Therapeutic Target for Ocular Neurodegenerative Diseases
Wang Y
Antioxidants (Basel, Switzerland) 2022; 11:
104954 Increased Risk of Ocular Hypertension in Patients with Cushing's Disease
Yichen M
Journal of Glaucoma 2022; 31: 941-946
104514 Review: The Development of Risk Factors and Cytokines in Retinal Vein Occlusion
Tang Y
Frontiers in medicine 2022; 9: 910600
104797 The application and progression of CRISPR/Cas9 technology in ophthalmological diseases
Hu X
Eye 2023; 37: 607-617
104910 Compound Heterozygous Variants of the Gene Co-Segregating in Two Chinese Pedigrees With Pigment Dispersion Syndrome/Pigmentary Glaucoma
Tan J
Frontiers in genetics 2022; 13: 845081
104515 Diabetic retinopathy with extensively large area of capillary non-perfusion: characteristics and treatment outcomes
Huang Z
BMC Ophthalmology 2022; 22: 293
104935 A review of study designs and data analyses in metabolomics studies in myopia
Hou XW
Analytical Biochemistry 2022; 655: 114850
104938 Genetic and clinical features of BEST1-associated retinopathy based on 59 Chinese families and database comparisons
Wang Y
Experimental Eye Research 2022; 223: 109217
105053 Outcomes of chronic angle-closure glaucoma treated by phacoemulsification and endocyclophotocoagulation with or without endoscopically goniosynechialysis
Wu X
International Journal of Ophthalmology 2022; 15: 1273-1278
104913 Prognostic Evaluation of Vitrectomy Assisted by Lucentis in Diabetic Retinopathy and Neovascular Glaucoma
Zhao X
Evidence-based Complementary and Alternative Medicine 2022; 2022: 4127293
104748 mTOR Signalling Pathway: A Potential Therapeutic Target for Ocular Neurodegenerative Diseases
Fung NSK
Antioxidants (Basel, Switzerland) 2022; 11:
104913 Prognostic Evaluation of Vitrectomy Assisted by Lucentis in Diabetic Retinopathy and Neovascular Glaucoma
Wang Y
Evidence-based Complementary and Alternative Medicine 2022; 2022: 4127293
104797 The application and progression of CRISPR/Cas9 technology in ophthalmological diseases
Zhang B
Eye 2023; 37: 607-617
104514 Review: The Development of Risk Factors and Cytokines in Retinal Vein Occlusion
Cheng Y
Frontiers in medicine 2022; 9: 910600
104938 Genetic and clinical features of BEST1-associated retinopathy based on 59 Chinese families and database comparisons
Jiang Y
Experimental Eye Research 2022; 223: 109217
105053 Outcomes of chronic angle-closure glaucoma treated by phacoemulsification and endocyclophotocoagulation with or without endoscopically goniosynechialysis
Wang Y
International Journal of Ophthalmology 2022; 15: 1273-1278
104935 A review of study designs and data analyses in metabolomics studies in myopia
Wang Y
Analytical Biochemistry 2022; 655: 114850
104910 Compound Heterozygous Variants of the Gene Co-Segregating in Two Chinese Pedigrees With Pigment Dispersion Syndrome/Pigmentary Glaucoma
Zeng L
Frontiers in genetics 2022; 13: 845081
104954 Increased Risk of Ocular Hypertension in Patients with Cushing's Disease
Chen Z
Journal of Glaucoma 2022; 31: 941-946
104515 Diabetic retinopathy with extensively large area of capillary non-perfusion: characteristics and treatment outcomes
Qiu K
BMC Ophthalmology 2022; 22: 293
104514 Review: The Development of Risk Factors and Cytokines in Retinal Vein Occlusion
Wang S
Frontiers in medicine 2022; 9: 910600
104515 Diabetic retinopathy with extensively large area of capillary non-perfusion: characteristics and treatment outcomes
Yi J
BMC Ophthalmology 2022; 22: 293
104935 A review of study designs and data analyses in metabolomics studies in myopia
Wu Q
Analytical Biochemistry 2022; 655: 114850
104910 Compound Heterozygous Variants of the Gene Co-Segregating in Two Chinese Pedigrees With Pigment Dispersion Syndrome/Pigmentary Glaucoma
Wang Y
Frontiers in genetics 2022; 13: 845081
104748 mTOR Signalling Pathway: A Potential Therapeutic Target for Ocular Neurodegenerative Diseases
Lam WC
Antioxidants (Basel, Switzerland) 2022; 11:
